Oragenics, Inc. (NYSE: OGEN) shares displayed a noteworthy resurgence during the extended trading period on Wednesday, marking a substantial 36.52% ascent to reach $3.14. This gain effectively counterbalanced the preceding 33.62% decline in the regular session, culminating in a closing price of $2.30. The recent announcement of an equity maneuver appears to have played a pivotal role in stabilizing OGEN stock after regular trading hours.

Last week, Oragenics (OGEN) disclosed the termination of its previously introduced "at-the-market" ("ATM") equity offering program. The company has initiated a 5-day termination process for the ATM offering, set to be effective on January 30, 2024. Notably, no sales were executed under the ATM offering during this specified period.

Furthermore, Oragenics has successfully concluded its previously disclosed acquisition of assets associated with Odyssey Health, Inc.'s proprietary neurological drug therapies and technologies. This includes ONP-002 and a distinctive nasal delivery device, serving as Odyssey's primary concussion asset and considered a pioneering intranasal drug for treating moderate-to-severe concussions in the acute through subacute phases.

The acquired assets also encompass all rights and interests in ONP-001, identified as a groundbreaking neurosteroid for addressing Niemann Pick Type-C Disease (NPC). Additionally, Odyssey's proprietary powder formulation and intranasal delivery device are part of the acquired assets, while Odyssey retains its remaining assets and operations.

Post the completion of this pivotal transaction, endorsed by favorable shareholder votes at both entities, Oragenics anticipates a substantial expansion in market opportunities through Odyssey's neurological pipeline. The company perceives that Odyssey's technology harmonizes with its proficiency in intranasal drug delivery, aiming to address a significant and escalating health concern.

The decision to invest in this innovative therapy underscores OGEN's commitment to pioneering solutions that leverage its intranasal drug delivery expertise, with the overarching goal of enhancing patient outcomes. The newly acquired pipeline candidates hold promise for delivering groundbreaking treatments to millions affected by mild traumatic brain injury (mTBI) and NPC, thus positioning Oragenics in a market poised to reach an annual valuation of $8.9 billion by 2027.